Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.69 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.69 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.69 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.69 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | HTR1B | P28222 | 4/20 | 0.58 |
| ▸ | HTR1D | P28221 | 6/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7115844 | 0.90 | TAAR1 (0.56) | TAAR1CYP2D6ADRA2AADRA2BADRA2C | |
| Tolazoline SCHEMBL34961 | 0.82 | TAAR1 (1.00) | TAAR1CYP2D6ADRA2AADRA2BADRA2C | |
| Tolazoline SCHEMBL34869 | 0.80 | TAAR1 (1.00) | TAAR1CYP2D6ADRA2AADRA2BADRA2C | |
| Tolazoline SCHEMBL9614505 | 0.80 | TAAR1 (1.00) | TAAR1CYP2D6ADRA2AADRA2BADRA2C | |
| Tolazoline SCHEMBL28254903 | 0.80 | TAAR1 (0.96) | TAAR1CYP2D6ADRA2AADRA2BADRA2C | |
| Tolazoline SCHEMBL5053858 | 0.80 | TAAR1 (1.00) | TAAR1CYP2D6ADRA2AADRA2BADRA2C | |
| SCHEMBL7010272 | 0.80 | TAAR1 (0.59) | TAAR1CYP2D6ADRA2AADRA2BADRA2C | |
| SCHEMBL10846015 | 0.78 | TAAR1 (0.72) | TAAR1CYP2D6ADRA2AADRA2BADRA2C | |
| SCHEMBL7005251 | 0.77 | HTR1D (0.58) | TAAR1CYP2D6ADRA2AADRA2BADRA2C | |
| SCHEMBL727185 | 0.74 | CYP1A2 (0.62) | CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030100769-A1 | Cyclic amidine compounds | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-05-29 | — | — | US | claimed |
| EP-1280793-A2 | CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUNTORY LIMITED (JP) | 2003-02-05 | — | — | EP | claimed |
| WO-2001081334-A2 | CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | claimed |
| US-20030100769-A1 | Cyclic amidine compounds | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-05-29 | — | — | US | disclosed |
| EP-1280793-A2 | CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUNTORY LIMITED (JP) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001081334-A2 | CYCLIC AMIDINE COMPOUNDS AND THEIR USE AS ALPHA4BETA2 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | SUNTORY LIMITED (JP) | 2001-11-01 | — | — | WO | disclosed |
| WO-1994006797-A1 | NOVEL BIOREDUCTIVE AGENTS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1994-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100769-A1 | Cyclic amidine compounds | CHRM1, CHRM5, CCKAR | TAAR1 65/4885CYP2D6 1900/4885ADRA2A 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.